CLICK “CONTINUE” AT THE BOTTOM OF THE PAGE TO COMPLETE YOUR REGISTRATION TO JOIN US IN BOSTON, MA.

CAN’T MAKE IT TO BOSTON? CLICK “CONTINUE” AT THE BOTTOM OF THE PAGE AND SELECT THE LIVE STREAMING OPTION TO PARTICIPATE VIRTUALLY.
 

Saturday, April 25, 2026
Buffet Dinner: 5:45 PM – 6:15 PM ET
Symposium: 6:15 PM – 7:45 PM ET

LIVE/LIVE STREAMING SYMPOSIUM

Omni Boston Hotel at the Seaport 
450 Summer St
Boston, MA 02210
Ensemble Ballroom B
 

Faculty 

Keisha L. Gibson, MD, MPH, FASN
Professor of Pediatrics
Senior Vice Chair of Clinical Affairs, Department of Pediatrics
Chief, Pediatric Nephrology
UNC Kidney Center
Chapel Hill, NC

William E. Smoyer, MD, FASN
C. Robert Kidder Chair
Director, Center for Clinical and Translational Research
The Research Institute at Nationwide Children’s Hospital
Professor of Pediatrics
The Ohio State University
Columbus, OH
 

Target Audience 

This activity has been designed to meet the educational needs of pediatric nephrology clinicians and pediatricians, including physicians, nurse practitioners, and PAs
 

Educational Provider

This activity is provided by Paradigm Medical Communications, LLC.  
 

Supporter Acknowledgment 

This activity is supported by an educational grant from Genentech, a member of the Roche Group.
 

Program Overview

Childhood idiopathic nephrotic syndrome (INS), the most common pediatric glomerular disease, is associated with high treatment-related morbidity. Although most patients attain remission with corticosteroid therapy, a subset experience frequently relapsing NS (FRNS) or steroid-dependent NS (SDNS), creating a complex and challenging treatment scenario requiring consideration of steroid-sparing strategies that are not without adverse effects. This symposium will review current guidelines for FRNS and SDNS, examine emerging clinical trial data on anti-CD20 therapies—including rituximab and investigational agents such as obinutuzumab—and address real-world treatment challenges through clinical case scenarios presented by our expert faculty.
 

Learning Objectives

Upon completion of this activity, participants should be able to:

• Outline the current guidelines for the treatment of FRNS and SDNS 
• Analyze the latest clinical trial data for emerging anti-CD20 monoclonal antibody agents for the treatment of FRNS and SDNS
• Individualize treatment of FRNS and SDNS

Agenda

• Welcome and Introductions
• Overview of FRNS and SDNS: Diagnostic Criteria and Immunology of INS
• Treatment Challenges in INS Relapse: Applying Current Guidelines and Recommendations
• Steroid-Sparing Agents in FRNS and SDNS: Clinical Data and Practice Considerations 
• Current and Emerging Anti-CD20 Therapies in FRNS and SDNS: Review of the Evidence
• Faculty Discussion and Conclusions

Physician Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Physician Credit Designation Statement

Paradigm Medical Communications, LLC designates this live activity for a maximum of 1 .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

PA Continuing Education 

PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
 

Nurse Practitioner Continuing Education 

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

 

Disclosure of Relevant Financial Relationships 

In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, Paradigm requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months. Disclosure information about relevant financial relationships with ineligible companies (if any) for anyone contributing to content development will be included in materials distributed at the time of the activity.
 

CME Inquires

For questions regarding CME credit, contact the Paradigm CME Department at cme@paradigmmc.com.
 

Fee Information

There is no fee required for participation in this activity.

Click the "Register Now" button. Once registered, you will receive an email confirmation with the event details.


© 2026 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.